SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis

Primary Care Diabetes

Volumn 12, Issue 3, 2018, Pages 265-283

  Seidu, Samuel ^a,b   Kunutsor, Setor K ^e,f   Cos, Xavier ^c   Gillani, Syed ^d   Khunti, Kamlesh ^a,b  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c RedIAPP   (Spain)

^d UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Renal impairment; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

ALBUMIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ARTICLE; COCHRANE LIBRARY; CREATININE BLOOD LEVEL; DATA EXTRACTION; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT; MACROALBUMINURIA; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PUBLICATION; SYSTEMATIC REVIEW; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; WEB OF SCIENCE; ADMINISTRATION AND DOSAGE; ADULT; AGED; DRUG EFFECT; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; MALE; MIDDLE AGED; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RISK ASSESSMENT; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85042441341     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2018.02.001     Document Type: Article

References (64)

1. Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103:2 (2014), 137–149.
2. Kramer, H., Molitch, M.E., Screening for kidney disease in adults with diabetes. Diabetes Care 28:7 (2005), 1813–1816.
3. Ariza, M.A., Vimalananda, V.G., Rosenzweig, J.L., The economic consequences of diabetes and cardiovascular disease in the United States. Rev. Endocr. Metab. Disord. 11:1 (2010), 1–10.
4. Li, R., Bilik, D., Brown, M.B., et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am. J. Manag. Care 19:5 (2013), 421–430.
5. Mata-Cases, M., Casajuana, M., Franch-Nadal, J., et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. Eur. J. Health Econ. 17:8 (2016), 1001–1010.
6. Chan, J.C., Scott, R., Arjona Ferreira, J.C., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10:7 (2008), 545–555.
7. Herrington, W.G., Nye, H.J., Aung, T., Metformin use in chronic kidney disease: new evidence to guide dosing. QJM 106:11 (2013), 1059–1061.
8. McGill, J.B., Sloan, L., Newman, J., et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 36:2 (2013), 237–244.
9. Schweizer, A., Dejager, S., Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther. 4:2 (2013), 257–267.
10. Chao, E.C., Henry, R.R., SGLT2 inhibition — a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 9:7 (2010), 551–559.
11. Bays, H., From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr. Med. Res. Opin. 25:3 (2009), 671–681.
12. Neal, B., Perkovic, V., de Zeeuw, D., et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 38:3 (2015), 403–411.
13. Yale, J.F., Bakris, G., Cariou, B., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 15:5 (2013), 463–473.
14. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345:12 (2001), 870–878.
15. de Zeeuw, D., Remuzzi, G., Parving, H.H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65:6 (2004), 2309–2320.
16. Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
17. Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 5, 2005, 13.
18. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7:3 (1986), 177–188.
19. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
20. Yale, J.F., Bakris, G., Cariou, B., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes. Metab. 16:10 (2014), 1016–1027.
21. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375:4 (2016), 323–334.
22. Haneda, M., Seino, Y., Inagaki, N., et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin. Ther. 38:1 (2016), 66–88 e20.
23. Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85:4 (2014), 962–971.
24. Kashiwagi, A., Takahashi, H., Ishikawa, H., et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes. Metab. 17:2 (2015), 152–160.
25. Barnett, A.H., Mithal, A., Manassie, J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2:5 (2014), 369–384.
26. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377 (2017), 644–657.
27. Stenlof, K., Cefalu, W.T., Kim, K.A., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes. Metab. 15:4 (2013), 372–382.
28. Lavalle-Gonzalez, F.J., Januszewicz, A., Davidson, J., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:12 (2013), 2582–2592.
29. Ferrannini, E., Seman, L., Seewaldt-Becker, E., Hantel, S., Pinnetti, S., Woerle, H.J., A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes. Metab. 15:8 (2013), 721–728.
30. Wilding, J.P., Norwood, P., T'Joen, C., Bastien, A., List, J.F., Fiedorek, F.T., A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32:9 (2009), 1656–1662.
31. List, J.F., Woo, V., Morales, E., Tang, W., Fiedorek, F.T., Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:4 (2009), 650–657.
32. Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W., List, J.F., Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:10 (2010), 2217–2224.
33. Bailey, C.J., Gross, J.L., Pieters, A., Bastien, A., List, J.F., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:9733 (2010), 2223–2233.
34. Bolinder, J., Ljunggren, O., Kullberg, J., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97:3 (2012), 1020–1031.
35. Strojek, K., Yoon, K.H., Hruba, V., Elze, M., Langkilde, A.M., Parikh, S., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 13:10 (2011), 928–938.
36. Rosenstock, J., Vico, M., Wei, L., Salsali, A., List, J.F., Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:7 (2012), 1473–1478.
37. Bode, B., Stenlof, K., Sullivan, D., Fung, A., Usiskin, K., Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp. Pract. (1995) 41:2 (2013), 72–84.
38. Cefalu, W.T., Leiter, L.A., Yoon, K.H., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382:9896 (2013), 941–950.
39. Kashiwagi, A., Kazuta, K., Takinami, Y., Yoshida, S., Utsuno, A., Nagase, I., Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol. Int. 6:1 (2015), 8–18.
40. Kashiwagi, A., Shiga, T., Akiyama, N., et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol. Int. 6:2 (2015), 104–116.
41. Kashiwagi, A., Akiyama, N., Shiga, T., et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetol. Int. 6:2 (2015), 125–138.
42. Haring, H.U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37:6 (2014), 1650–1659.
43. Haring, H.U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36:11 (2013), 3396–3404.
44. Haering, H.U., Merker, L., Christiansen, A.V., et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 110:1 (2015), 82–90.
45. Kovacs, C.S., Seshiah, V., Swallow, R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes. Metab. 16:2 (2014), 147–158.
46. Wilding, J.P., Charpentier, G., Hollander, P., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int. J. Clin. Pract. 67:12 (2013), 1267–1282.
47. Forst, T., Guthrie, R., Goldenberg, R., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes. Metab. 16:5 (2014), 467–477.
48. Rosenstock, J., Jelaska, A., Frappin, G., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37:7 (2014), 1815–1823.
49. Rosenstock, J., Jelaska, A., Zeller, C., et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 17:10 (2015), 936–948.
50. Lu, C.H., Min, K.W., Chuang, L.M., Kokubo, S., Yoshida, S., Cha, B.S., Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig. 7:3 (2016), 366–373.
51. Seino, Y., Sasaki, T., Fukatsu, A., Sakai, S., Samukawa, Y., Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30:7 (2014), 1219–1230.
52. Seino, Y., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., Samukawa, Y., Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30:7 (2014), 1231–1244.
53. Seino, Y., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., Samukawa, Y., Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr. Med. Res. Opin. 30:7 (2014), 1245–1255.
54. Kaku, K., Watada, H., Iwamoto, Y., et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc. Diabetol., 13, 2014, 65.
55. Nauck, M.A., Del Prato, S., Meier, J.J., et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:9 (2011), 2015–2022.
56. Tikkanen, I., Narko, K., Zeller, C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38:3 (2015), 420–428.
57. Kadowaki, T., Haneda, M., Inagaki, N., et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv. Ther. 31:6 (2014), 621–638.
58. Rosenstock, J., Aggarwal, N., Polidori, D., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:6 (2012), 1232–1238.
59. Ridderstrale, M., Andersen, K.R., Zeller, C., et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2:9 (2014), 691–700.
60. Inagaki, N., Kondo, K., Yoshinari, T., Takahashi, N., Susuta, Y., Kuki, H., Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin. Pharmacother. 15:11 (2014), 1501–1515.
61. Yamout, H., Perkovic, V., Davies, M., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am. J. Nephrol. 40:1 (2014), 64–74.
62. Cherney, D., Lund, S.S., Perkins, B.A., et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59:9 (2016), 1860–1870.
63. Andrianesis, V., Glykofridi, S., Doupis, J., The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther. Adv. Endocrinol. Metab. 7:5–6 (2016), 212–228.
64. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373:22 (2015), 2117–2128.